Full-Time
Engineering Technician
Posted on 9/9/2025
Integer Holdings Corporation
1,001-5,000 employees
Medical device CDMO for cardiac devices
Compensation Overview
$46.5k - $68.2k/yr
Corfu, NY, USA
In Person
 Mechanical Engineering (2) |
|---|
| , |
- Associate’s degree in technical field with 3-5 years relevant experience OR a high school graduate with 7-10 years relevant experience
- Ability to read technical drawings/prints
- Computer operation skills
- Mechanical aptitude
- Excellent organizational and communication skills – written and verbal
- Performs semi-standardized or semi-prescribed assignments requiring judgmental and problem solving skills
- Adheres to GB Core Beliefs and all safety and quality requirements
- Sets up and runs experiments and/or tests apparatus with direction
- Designs, recommends, assembles, and installs equipment/apparatus and processes for product fabrication, research and development, or analysis and testing
- Writes instructions and trains personnel in proper techniques to utilize systems, equipment, and processes
- Troubleshoots and may repair, modify, and/or maintain systems and/or equipment
- Provides input in evaluation of equipment and processes
- Writes technical reports and other required documentation
- Interacts with and advises other departments
- Performs other functions as required
Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wilmington, Delaware
Founded
1940
Simplify's Take
What believers are saying
- Board initiated strategic review on April 30, 2026, exploring sale options.
- Irenic Capital acquired $99M stake in Q4 2025 as top holding.
- $200M share repurchase authorization signals management confidence in valuation.
What critics are saying
- Class action lawsuits by Pomerantz and Bleichmar drain cash via settlements by Q4 2026.
- Three new products cause 3-4% headwind, slashing H2 2026 margins.
- Irenic activism forces sale at depressed valuation below $93 target in 12 months.
What makes Integer Holdings Corporation unique
- Integer specializes in contract manufacturing for Cardio & Vascular medical devices.
- Organic revenue grew 1.3% in Q1 2026 despite flat overall sales.
- Robust pipeline targets above-market growth by 200 basis points in 2027.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Adoption Assistance
Parental Leave
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Integer Holdings Corporation shares fell 28% following an insider sale disclosure. Tom Thomas, the company's vice president and corporate controller, sold 825 shares of common stock in an open-market transaction on 13 March 2026, according to an SEC Form 4 filing. The transaction was valued at $70,000 at a reported price of $85 per share. The sale represented 15.85% of Thomas's direct holdings at the time. Following the transaction, Thomas holds 4,380 shares worth approximately $364,000. This marks Thomas's third open-market sale since 2018, following previous sales of 884 shares in November and 1,500 shares in April. Integer Holdings manufactures medical devices and components, generating $1.85 billion in trailing twelve-month revenue.
Integer Holdings, a medical device manufacturer, reported fourth quarter revenue of $472.1 million and adjusted earnings per share of $1.76, both exceeding analyst expectations. The company posted 5% year-on-year revenue growth, driven by strong performance in its Cardio & Vascular segment. CEO Peyman Khales attributed $30 million in operational improvements to higher sales volume, manufacturing efficiencies and expense management. The company guided adjusted earnings per share of $6.54 for 2026, beating analyst estimates by 3.8%. During the earnings call, analysts questioned the narrowing of organic sales guidance, first quarter margin compression and the company's path to above-market growth in 2027. Management emphasised collaborative customer planning and reaffirmed its current strategy despite activist investor involvement.
Irenic Capital Management has acquired a $99.11 million stake in Integer Holdings, purchasing 1,263,663 shares in Q4 2026. The position represents 13.7% of Irenic's assets under management, making it the fund's largest disclosed equity holding. Integer Holdings, a medical device company, achieved 8% sales growth in 2025, reaching $1.85 billion in revenue, with adjusted earnings per share rising 21% to $6.40. The company reported fourth-quarter sales of $472 million and net income of $62 million, up 22% year-over-year. Management projects 2026 adjusted earnings per share between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027. Benchmark analyst Robert Wasserman upgraded the stock from hold to buy with a $95 price target.
Integer Holdings reported strong 2025 results with sales up 8% and adjusted earnings per share rising 21% to $6.40, alongside margin expansion and $105 million in free cash flow. The company returned capital through a $50 million share repurchase and announced an additional $50 million accelerated share repurchase programme. However, management warned that three newer products representing approximately 6% of 2025 sales are experiencing slower-than-expected adoption, creating a 3%–4% headwind for 2026. The company expects flat-to-slightly-down sales and a 200–250 basis point hit to first-quarter operating margin, with recovery and margin expansion anticipated in the second half. Integer maintained its 2026 midpoint guidance, with year-end net debt expected at $1.17–1.19 billion and net leverage remaining at 3.0 times adjusted EBITDA.
Integer Holdings, a medical device contract manufacturing organisation, reported fourth-quarter sales of $472 million, up 5% year-over-year, with adjusted earnings per share at the high end of its October guidance range. For the full year 2025, sales increased 8% on a reported basis and over 6% organically, whilst adjusted operating income rose 13%. The company issued 2026 guidance expecting reported sales to be down 1% to up 1%, with a 3% to 4% headwind from three new products facing lower-than-expected market adoption. However, Integer's underlying business is expected to grow 4% to 6%, in line with the market. Integer repurchased $50 million of shares in Q4 and announced plans for an additional $50 million accelerated share repurchase programme under its $200 million authorisation.